1,000
Participants
Start Date
April 1, 2025
Primary Completion Date
September 1, 2027
Study Completion Date
September 1, 2030
Circulating Tumor DNA (ctDNA) Assay
Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.
NOT_YET_RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
NOT_YET_RECRUITING
Massachusetts General Hospital, Boston
NOT_YET_RECRUITING
Dana-Farber Cancer Institute at Steward St. Elizabeth's, Brighton
NOT_YET_RECRUITING
Dana-Farber Cancer Instiute Merrimack Valley, Methuen
NOT_YET_RECRUITING
Dana-Farber Cancer Institute South Shore, South Weymouth
Collaborators (1)
Beth Israel Deaconess Medical Center
OTHER
Boston Medical Center
OTHER
Massachusetts General Hospital
OTHER
Dana-Farber Cancer Institute
OTHER